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Luciferase) and A56 (hemagglutinin, HA) proteins interact and together prevent cell–cell
fusion. SPI-3/A56 has been proposed to prevent the superinfection of previously infected cells by reducing
virus–cell fusion. Binding of mature virions of vaccinia virus (VV) to VV-infected cells was unaffected by SPI-3
or A56 on the surface of infected cells. Entry of VV into infected cells was assessed using VV-PT7-luc carrying
the luciferase reporter under T7 control. Cells infected with VV or cowpox virus (CPV) expressing T7 RNA
polymerase and lacking SPI-3 and/or A56 were superinfected with VV-PT7-luc, and luciferase activity was
measured. Inactivation of SPI-3 or A56 from the pre-infecting virus resulted in greater luciferase expression
from the superinfecting VV-PT7-luc. Antibody against SPI-3 present during infection with wild-type CPV-T7
increased luciferase expression from superinfecting VV-PT7-luc. The SPI-3/A56 complex on the infected cell
surface therefore appears to reduce the entry of virions into infected cells.
© 2008 Elsevier Inc. All rights reserved.Introduction
Vaccinia virus (VV), the prototypic orthopoxvirus, belongs to the
same genus as cowpox virus (CPV) and variola virus, the causative
agent of smallpox (Moss, 2001). Poxviruses have large, complex
virions with dsDNA genomes, but replicate within the cytoplasm of
the infected cell. Many details of VV transcription and DNA replication
are known, but the lists of virus proteins required for virion
morphogenesis (Smith et al., 2002; Condit et al., 2006) and entry
into cells (Moss, 2006) are still being compiled.
The most important forms of poxvirus virions are the intracellular
form MV (mature virus, formerly IMV) and the extracellular form EV
(extracellular virus, formerly EEV). Both forms are membrane-
wrapped, but EV contains an additional membrane envelope relative
to MV, and the protein compositions of the outer membranes of EV
and MV are distinct (Condit et al., 2006). The EV surface carries virus
glycoproteins including B5, A33, and A34, together with the non-
essential hemagglutinin (HA) encoded by the A56R gene (Payne,
1979), which is associated with the serpin SPI-3 (K2) (Brum et al.,
2003; Turner and Moyer, 2006). In contrast the MV surface has no
glycoproteins, but MV particles like EV are fully infectious. In nature,oyer@mgm.uﬂ.edu
l rights reserved.the EV form is responsible for virus spread within an infected host
(Payne,1980), and the stableMV formmediates spread between hosts.
Recently a group of highly conserved genes has been identiﬁed
whose products are required for entry of MV into cells (Moss, 2006),
including A28 (Senkevich et al., 2004), H2 (Senkevich and Moss,
2005), A21 (Townsley et al., 2005b), L5 (Townsley et al., 2005a), A16
(Ojeda et al., 2006b), G3 (Izmailyan et al., 2006), G9 (Ojeda et al.,
2006a), and J5, all of which are components of an entry-fusion
complex (Senkevich et al., 2005). Mutation in any one of these genes
(except for J5, which to our knowledge has not yet been tested) results
in the synthesis of morphologically normal MV that can bind to cells
but cannot enter (Moss, 2006). In addition, a mutation in F9, a sub-
stoichiometric component of the complex that resembles the L1
morphogenesis protein, results in a similar phenotype (Brown et al.,
2006). A mutant in I2 behaves in the same fashion (Paula Traktman,
pers. comm.).
MV is thought to enter cells by fusion with a cellular membrane,
either directly at the cell surface at neutral pH, or at low pH within an
endosome. Cell–cell fusion can be mediated by virions bound to the
cell surface following a brief acid treatment. Low pH-triggered fusion
of cells occurs following binding of exogenous puriﬁed MV to cells at
very high multiplicity (“fusion from without”), or following natural
infection with synthesis and deposition of virus particles (presum-
ably EV) at the cell surface (“fusion from within”). Mutant virions
lacking any one of the entry proteins tested to date are defective both
in fusion from without and fusion from within (Moss, 2006),
Fig. 1. Binding of VV A5-YFP MV particles to uninfected and VV-infected CV-1 cells. (A–C) CV-1 cells were either uninfected (A) or infected with VV-T7 (B) or VV-T7 ΔA56 (C). At
16 h p.i., VV A5-YFP was adsorbed for 1 h at room temperature. Unadsorbed virus was removed by washing, and the cells stained with DAPI. The images shown are merges of the
DAPI blue channel (nuclei) and the FITC green channel (bound virions). (D) CV-1 cells in 12-well plates were mock-infected or infected with VV-T7 or with mutant derivatives
lacking either SPI-3, A56, or both. At 16 h p.i., puriﬁed MV of VV A5-YFP was adsorbed to the cells at room temperature for 1 h. After washing to remove unadsorbed virions, cells
were DAPI-stained, harvested, and transferred to a black 96-well plate to measure by ﬂuorescence the amount of YFP (representing bound virus) and DAPI (number of cell nuclei).
The results are expressed as the ratio of YFP/DAPI ﬂuorescence. Error bars represent the standard deviation.
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triggered by low pH.
The entry of EV into cells starts with the attachment of EV to the
cell membrane, then the non-fusogenic dissolution of the EV outer
membrane bilayer, which produces a “shroud” covering the resulting
MV at the cell surface (Law et al., 2006). From this point the entry
process is proposed to be the same as for MV. Two of the components
of the EV envelope, the A56 and SPI-3 proteins, inhibit the process of
cell–cell fusion. Mutation in either A56 (Ichihashi and Dales, 1971) or
SPI-3 (Turner and Moyer, 1992; Law and Smith, 1992; Zhou et al.,
1992) results in extensive cell–cell fusion following infection at
neutral pH. A56 and SPI-3 are present both on the surface of EV and
on the surface of infected cells (Payne, 1979; Brum et al., 2003), and
the two proteins colocalize on the cell membrane by confocal
microscopy (Brum et al., 2003). Co-immunoprecipitation studies
indicate that SPI-3 and A56 interact (Turner and Moyer, 2006). SPI-3,
which contains a signal sequence but lacks a transmembrane
domain, is only detected on the cell membrane when A56 is present
(Brum et al., 2003). Removal of the transmembrane domain from A56
results in cell–cell fusion (Turner and Moyer, 2006), suggesting that
the A56/SPI-3 complex must be membrane-localized for fusion
inhibition.
Wagenaar and Moss (2007) showed that the proteins of the entry
complex co-puriﬁed with A56 when TAP (tandem afﬁnity puriﬁca-
tion) epitope tags were appended to A56, provided that SPI-3 was
present. Similarly entry proteins co-puriﬁed with TAP-tagged SPI-3
(K2) in the presence of A56; and SPI-3 and A56 were co-puriﬁed
with TAP-tagged A28, along with entry proteins (Wagenaar andMoss, 2007). However, in infected cells SPI-3/A56 would not
normally be expected to come into contact with the entry/fusion
complex.
The most likely natural scenario for interaction between SPI-3/A56
and the entry/fusion complex is when virions are about to enter a
previously infected cell, i.e. superinfection. The ﬁrst infecting virus
frequently prevents the replication of superinfecting virus by an
exclusionmechanism. Precedents for superinfection exclusion include
inﬂuenza virus, which expresses a neuraminidase that inactivates the
cell surface receptor required for virus entry (Palese et al., 1974),
vesicular stomatitis virus (Whitaker-Dowling et al., 1983), and herpes
virus, whose glycoprotein D at the cell surface interferes with
penetration of superinfecting virus (Johnson and Spear, 1989). Super-
infection exclusion operates in VV based on experiments involving
infection with wt VV and superinfecting with VV-lacZ at different
times after the initial infection (Christen et al., 1990). The lacZ reporter
was driven either by the early/late TK promoter or the late P11
promoter. By titering lacZ+ virus, the replication of the superinfecting
virus was reduced by 90% 4 h after the ﬁrst infection, and by N99%
after 6 h (Christen et al., 1990). Prior infection did not prevent
adsorption of the superinfecting virus, but early gene transcription
was abolished when superinfecting virus was added 6 h after the
initial infection, indicating that the block occurs in between adsorp-
tion and early transcription (Christen et al., 1990). Reductions in the
rates of virus entry, uncoating or early transcription would be
consistent with published data on superinfection exclusion. The
phenomenon may involve a combination of these distinct
mechanisms.
Fig. 2. Expression of luciferase in CV-1 and in BSR-T7 cells following infection with VV-PT7-luc, and the effect of AraC on luciferase expression by infected BSR-T7 cells. (A) CV-1 and
BSR-T7 cells were infectedwith VV-PT7-luc at moi=10, and luciferase activitywas determined at intervals. (B, C). Expression of luciferase by VV-PT7-luc in BSR-T7 cells in the presence
and absence of 40 μg/ml AraC. The time course from 0 to 6 h p.i. is shown (B), with an enlargement of the time course from 0 to 3 h (C).
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infected cells in reducing superinfection, by an apparent slowing
down of the entry/fusion process. Binding of SPI-3 and A56 to proteins
in the entry complex of incoming virions is a likely mechanism for
reduction in the entry rate.
Results
Binding of superinfecting VV-A5-YFP to cells pre-infected with VV-T7 was
not affected by the absence of SPI-3 or A56 from the pre-infecting virus
Under a normal infection, the entry complex on the surface of MV
and the SPI-3/A56 pair on the outer membrane of EV and on the
surface of infected cells are probably never directly adjacent. The most
likely circumstance for interactionwould be when a virion (either MV,or EV with a disrupted outer envelope) has attached to a previously
infected cell, and is poised to enter by fusionwith the cell or endosome
membrane. If SPI-3 and A56 on the surface of infected cells reduce
superinfection, as proposed by our laboratory and others (Moss, 2006;
Turner and Moyer, 2006), the proteins could operate at the level of
virus binding or entry or both.
To investigate binding of mature virions to infected cells, we used
VV-A5-YFP in which the A5 core protein (A4 in Copenhagen
nomenclature) has been fused to yellow ﬂuorescent protein (Katsa-
fanas and Moss, 2007). Virions of VV A5-YFP can be directly detected
by ﬂuorescence without immunostaining. CV-1 cells were infected
with VV-T7 or with derivatives lacking either SPI-3, A56, or both, and
at 16 h p.i. mature virions of VV A5-YFP were adsorbed for 1 h at room
temperature. Cell–cell fusion caused by infection with VV-T7 SPI-3 or
A56 mutants at the 16 h time point was incomplete, with variable
Fig. 3. Expression of luciferase from VV-PT7-luc depends on the multiplicity of
superinfection. CV-1 cells infected with VV-T7 at moi=5 were superinfected at 16 h p.i.
with VV-PT7-luc at multiplicities of 25, 50, 100, and 300 in the presence of AraC, and
luciferase expression followed at intervals. The data for luciferase expression at 3 h and
at 4 h post adsorption of VV-PT7-luc were plotted as a function of multiplicity, and linear
trendlines ﬁtted (dashed lines). The R2 values indicate how closely the values ﬁt a linear
trendline.
Fig. 4. Comparison of luciferase expression after infection with VV-T7 or with
derivatives lacking SPI-3 or A56, and superinfection with VV-PT7-luc. CV-1 cells in 96-
well plates were infected with VV-T7, VV-T7ΔSPI-3, VV-T7ΔA56, or VV-T7ΔSPI-3 ΔA56
at moi=5, and at 16 h p.i. superinfected with VV-PT7-luc at moi=100. Luciferase activity
was determined at the indicated time points after adsorption of the superinfecting
virus. Each time point shows the mean of 4 wells, plus and minus the standard
deviation.
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p.i. fusion triggered by the mutants was complete (data not shown).
There is no SPI-3 or A56 present in the VV A5-YFP MV used in this
experiment as the intracellular form of virus lacks both proteins
(Payne, 1979; Brum et al., 2003). After washing to remove unbound
virus, the cells were stained with DAPI. Green virions of VV A5-YFP
bound to uninfected cells (Fig. 1A) were readily visible using FITC
ﬁlters. Although binding to infected cells appeared to be reduced
relative to uninfected cells, no obvious differences in the extent of
binding were visible by microscopy that depended on the genotype of
the ﬁrst infecting virus (Figs. 1A–C). Virion binding to cells pre-
infected with VV-T7 (Fig. 1B) appeared to be similar to binding to the
syncytia resulting from infection of cells with virus lacking A56 (Fig.
1C), as did binding to cells infected with VV-T7ΔSPI-3 or with VV-
T7ΔSPI-3ΔA56 (data not shown). The extent of VV A5-YFP bound per
cell was compared by harvesting the cells and measuring the ratio of
YFP: DAPI ﬂuorescence. The results (Fig. 1D) indicated that there was a
slight decrease in the extent of virus binding when VV-T7-infected
cells were compared with uninfected cells. However, there was no
signiﬁcant increase or decrease in the amount of virus binding caused
by deletion from the pre-infecting virus of SPI-3 or A56 or both (Fig.
1D), suggesting that the presence of SPI-3/A56 on infected cells does
not affect binding of superinfecting virus.
Evaluation of a VV recombinant with a T7-driven luciferase gene for
measuring virus superinfection
To measure entry of virions into cells pre-infected with VV-T7
derivatives, we constructed a VV recombinant carrying the luciferase
reporter under the control of the T7 promoter. Entry of such virions
into a cytoplasm containing T7 RNA polymerase should give rapid and
robust luciferase expression upon uncoating, and transcription of
luciferase should not compete with pre-existing VV genes for
transcription. The T7 promoter was used to drive luciferase rather
than a poxvirus early promoter to avoid the block to early transcrip-
tion observed following superinfection (Christen et al., 1990).
The luciferase gene was inserted into the transfer plasmid pTM1,
and the resulting PT7-luciferase cassette was introduced into the VV-WR genome by homologous recombination between the TK ﬂanks.
The VV-PT7-luc recombinant gave a very low background of luciferase
expression on infection of CV-1 cells lacking the T7 RNA polymerase,
but gave substantial luciferase activity after infection of BSR-T7 cells
expressing T7 RNA polymerase constitutively (Fig. 2A), indicating that
the luciferase gene was tightly regulated. Luciferase synthesis
resulting from infection of BSR-T7 cells with VV-PT7-luc was still
detectable at early times (b3 h) in the presence of the DNA synthesis
inhibitor cytosine arabinoside (AraC), which blocks late gene expres-
sion (Figs. 2B, C). The sensitivity of the luciferase reporter enabled
early detection of luciferase expression from incoming virus genomes
in the absence of virus DNA replication. AraC was used in all
subsequent experiments to block possible DNA replication of super-
infecting virus genomes.
Pilot experiments showed that infection of CV-1 cells with VV-T7
expressing T7 RNA pol followed by superinfection at 16 h p.i. with VV-
PT7-luc gave appreciable luciferase expression. The extent of luciferase
expression at 3 h p.i. and at 4 h p.i. was found to be related to the
multiplicity of superinfection in a linear fashion, over a range of moi
from 25 to 300 (Fig. 3). The characteristics of VV-PT7-luc were
therefore suitable to assess virus entry into cells pre-infected with VV
recombinants expressing T7 RNA pol.
Entry of superinfecting virus is reduced by the presence of SPI-3 and A56
during the primary infection
The effects of SPI-3 and A56 in the primary infecting virus on
subsequent superinfection were evaluated by constructing VV-T7
derivatives lacking either SPI-3 (VV-T7ΔSPI-3), A56 (VV-T7ΔA56) or
both (VV-T7ΔSPI-3 ΔA56). CV-1 cells were grown in 96-well plates for
3 days to give dense and tightly-attachedmonolayers, then infected at
moi=5 with the parental virus VV-T7 or with each of the mutant
derivatives. At 16 h p.i., the cells were superinfectedwith VV-PT7-luc at
moi=100 in the presence of AraC. Luciferase activity was determined
at intervals by adding BriteLite luciferase reagent directly to the wells
and measuring luminescence. Under these conditions, the extent of
cell–cell fusion observed with VV-T7 derivatives lacking SPI-3, A56, or
both was minimal (Supplementary Fig. 1). Fusion mediated by VV SPI-
3 or A56 mutants at neutral pH is much slower than is seen with CPV
mutants (Turner and Moyer, 1992), and complete fusion is not seen
until 48 h p.i.
Fig. 5. Luciferase expression after infection with VV-T7ΔSPI-3, transfection with
plasmid DNAs carrying SPI-3 mutants, and superinfection with VV-PT7-luc. 96-well
plates of CV-1 cells were infected with VV-T7ΔSPI-3 at moi=5, transfected with the
indicated plasmid DNAs, and at 16 h p.i. superinfected with VV-PT7-luc at moi=100.
Luciferase expression was measured at 2 h after adsorption of the superinfecting virus.
Each bar shows the mean of 3 wells, plus and minus the standard deviation.
Fig. 6. Luciferase expression following superinfection of cells infected with CPV-T7
derivatives. (A) CV-1 cells were infected with either CPV-T7 expressing the T7 RNA
polymerase or with derivatives lacking SPI-3, A56, or both. At 16 h p.i. the cells were
superinfected with VV-PT7-luc, and luciferase activity determined at the indicated time
points, as for the VV-T7 series in Fig. 4. (B) Cells were infected with CPV-T7 or CPV-
T7ΔSPI-3 in the absence or presence of 10 μg/ml puriﬁed anti-SPI-3 mAb. Superinfecting
VV-PT7-luc was added at 16 h p.i. and luciferase activity was determined at intervals
after the end of the adsorption period. SPI-3 mAbwas present during adsorption of VV-
PT7-luc and during subsequent incubation at 37 °C in the treated wells. Error bars
indicate the standard deviation.
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the superinfecting VV-PT7-luc virus, and hence virus entry, was more
rapid and occurred to a greater extent when SPI-3, A56 or both genes
were absent from the primary infecting virus. No appreciable
differences were noted between cells infected with VV-T7ΔSPI-3
ΔA56 and cells infected with either single mutant (Fig. 4), suggesting
that SPI-3 and A56 act together to reduce the rate of virus entry.
Control experiments to measure the level of T7 RNA polymerase
expression in infected cells by transfection of pTM1-luc plasmid DNA
showed that luciferase levels were identical for VV-T7, VV-T7ΔSPI-3,
VV-T7ΔA56, and the double mutant (data not shown), as would be
expected since each virus contained the same T7 RNA polymerase
gene 1 driven by the same P7.5 early/late promoter in the TK gene
(Fuerst et al., 1986). The data of Fig. 4 suggest that both SPI-3 and A56
are required to reduce virion entry into infected cells.
SPI-3 mutants defective in proteinase inhibition are active in reducing
luciferase expression by superinfecting virus
The observed inhibition of cell–cell fusion by SPI-3 and A56 is
consistent with SPI-3/A56 slowing the rate at which bound virions
fuse with the infected cell membrane. The serpin SPI-3 is known to be
a functional inhibitor of the proteinases tissue-type plasminogen
activator, urokinase-type plasminogen activator, and plasmin (Turner
et al., 2000). However, site-directed CPV SPI-3 mutants in the
conserved reactive center loop (RCL) are active in preventing cell-
cell fusion, despite being inactive as proteinase inhibitors (Turner and
Moyer, 1995). The CPV SPI-3 mutants with substitutions at the P1/P1′
positions and the P5 through P5′ positions in the RCL were tested for
their ability to reduce reporter expression from superinfecting virus
by a transfection assay. CV-1 cells were infectedwith VV-T7ΔSPI-3 and
immediately transfected with plasmid DNAs derived from pSC65
(Chakrabarti et al., 1997) carrying either CPV wt SPI-3 or the P1/P1′ or
P5/P5′ mutant. Control transfections used pSC65 carrying no inserted
gene, or with gfp or CPV A56. In all cases the inserted gene was
coupled to a synthetic early/late VV promoter (Chakrabarti et al.,
1997). Luciferase expression was measured at 2 h after superinfection
of infected/transfected cells with VV-PT7-luc. Treatment with thetransfection reagent Lipofectamine 2000 alone did not diminish
luciferase expression from VV-T7ΔSPI-3 infected cells superinfected
with VV-PT7-luc, and likewise transfection with empty vector, pSC65-
gfp, or pSC65-A56 had no effect (Fig. 5). However, transient expression
of wt SPI-3 from pSC65-SPI-3 did markedly reduce luciferase activity,
showing that CPV SPI-3 was able to substitute for VV SPI-3 in this
assay. The CPV SPI-3 P1/P1′ and SPI-3 P5/P5′mutants were also active
in reducing luciferase expression following VV-PT7-luc superinfection
of cells infected with VV-T7ΔSPI-3 (Fig. 5). The evidence suggested
that the P1/P1′ and P5/P5′ SPI-3 mutants were able to reduce entry of
VV-PT7-luc into infected cells by virus-cell fusion, in the absence of
proteinase inhibition, consistent with their known ability to prevent
cell–cell fusionwhen transfected into cells infected with VV-T7ΔSPI-3
(Turner and Moyer, 1995).
The presence of SPI-3 mAb during superinfection of CPV-T7-infected cells
with VV-PT7-luc increases the rate of superinfecting virus entry
The mAb 4A11-4A3 against cowpox virus SPI-3 has been shown to
block the inhibitory effect of SPI-3 upon cell–cell fusion. Cells infected
Fig. 7. The effect of low pH treatment on cells infected with VV-T7 or VV-T7ΔSPI-3 ΔA56
and superinfected with VV-PT7-luc. CV-1 cells were infectedwith VV-T7 or VV-T7ΔSPI-3
ΔA56 and at 16 h p.i. superinfected with VV-PT7-luc. Cells were treated with pH 7 or pH
5 buffer for 3 min at room temperature either immediately before or after adsorption of
VV-PT7-luc, as indicated below the axis. Luciferase activity was measured at 2.5 h after
the end of the adsorption period.
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in contrast with the lack of fusion seen in the absence of SPI-3 mAb
(Turner and Moyer, 2006). By immunoﬂuorescence the SPI-3 mAb is
only detected on the surface of cells under these conditions, and the
mAb is presumably exerting its effect by binding to SPI-3 protein
present on the cell membrane, and not by entering infected cells.
If the SPI-3 protein on the surface of infected cells is reducing
superinfection by slowing the rate of fusion of incoming virions with
the cell membrane, we might predict that SPI-3 mAb would diminish
this effect, and therefore increase the rate of luciferase expression
following superinfection with VV-PT7-luc. The SPI-3 mAb reacts much
more strongly with CPV SPI-3 than with VV SPI-3 (data not shown),
and we therefore tested this hypothesis by constructing CPV-T7, a SPI-
3+ A56+ recombinant expressing T7 RNA polymerase, and a derivative
CPV-T7ΔSPI-3 lacking SPI-3. The SPI-3 mAb should have no effect on
luciferase expression following superinfection of cells infected with
CPV-T7ΔSPI-3. CPV-T7 derivatives lacking A56 or both SPI-3 and A56
were also constructed. The amount of cell-cell fusion at 16 h after
infectionwith CPV-T7 lacking SPI-3 and/or A56 (Supplementary Fig. 2)
was much greater than with the corresponding VV-T7 mutants
(Supplementary Fig. 1).
The extent of superinfection of cells ﬁrst infected with CPV-T7 or
CPV-T7ΔSPI-3 was assessed using VV-PT7-luc (Fig. 6A), as in Fig. 4 for
the VV-T7 series. The extent of luciferase expression was increased
when CPV-T7ΔSPI-3-infected cells were compared with cells infected
with CPV-T7 (Fig. 6A). A similar increase was seen with cells pre-
infected with CPV-T7ΔA56 or with CPV-T7ΔSPI-3 ΔA56 (Fig. 6A).
These results indicate that the CPV SPI-3 and A56 appear to reduce
superinfection in an identical fashion to their VV counterparts. The
magnitude of the increase in luciferase expression following deletion
of SPI-3 and/or A56 from CPV-T7 (Fig. 6A) was very similar to that seen
after inactivation of SPI-3 and/or A56 in VV-T7 (Fig. 4). The fact that
similar increases in reporter gene expression were seen despite the
greater cell-cell fusion seen with the CPV-T7 mutants relative to the
VV-T7 mutants (Supplementary Figs. 1 and 2) argues that increased
luciferase activity reﬂected increased virus entry, and was not an
indirect consequence of cell–cell fusion.
The SPI-3 mAb was tested for its effect on the rate of luciferase
expression following VV-PT7-luc superinfection of cells infected with
either CPV-T7 or CPV-T7ΔSPI-3 (Fig. 6B). SPI-3 mAb had no effect on
the luciferase expression measured following superinfection of CPV-
T7ΔSPI-3-infected cells (Fig. 6B), indicating that the antibody by itself
does not affect virus binding or entry. In contrast, the presence of SPI-3
mAb prior to and during superinfection of cells infected with CPV-T7
did increase luciferase expression, to an extent intermediate between
the low level for CPV-T7 and the higher level for CPV-T7ΔSPI-3 (Fig.
6B). This result supports the model that SPI-3 present in the infected
cell is mediating its effect on superinfection at the cell surface, and not
by some indirect mechanism within the cytoplasm.
Low pH treatment accelerates the entry of VV-PT7-luc bound to
pre-infected cells, but does not eliminate reduction in
luciferase expression caused by SPI-3/A56
The fact that fusion from within following low pH treatment of
infected cells occurs in the presence of SPI-3 and A56 on the cell
surface suggests that the apparent inhibitory effects of SPI-3/A56 on
virus fusion might be eliminated following exposure to acid condi-
tions. Low pH accelerates the entry of VV into cells (Townsley et al.,
2006), apparently both by unmasking the fusion complex on virions,
and by stimulating fusion of virions bound at the cell surface
(Townsley and Moss, 2007). To investigate the effect of low pH
treatment on superinfection, cells were infected with VV-T7, super-
infected with VV-PT7-luc at 16 h p.i., and treated for a short period
with pH 7 or pH 5 buffer. Low pH treatment of cells was either before
the adsorption of the superinfecting virus, or immediately followingadsorption. Luciferase expression was measured at 2.5 h after the end
of the adsorption. Treatment of VV-T7-infected cells at pH 5 prior to
adsorption had no effect on the level of luciferase expression after
superinfection (Fig. 7). However, treatment at pH 5 of VV-T7-infected
cells to which VV-PT7-luc virions had been bound did increase
luciferase expression relative to a pH 7 treated control (Fig. 7),
consistent with acceleration of virus entry.
Cells pre-infected with VV-T7ΔSPI-3ΔA56 were similarly super-
infected and treated at pH 7 or 5 before or after adsorption of VV-PT7-
luc (Fig. 7). Low pH treatment of cells infected with the double mutant
prior to superinfection did not result in increased luciferase expres-
sion relative to the pH 7 control (Fig. 7). Note that the luciferase level
was higher for cells treated pre-adsorption at pH 7 or 5 when the ﬁrst
infection was with VV-T7ΔSPI-3ΔA56 compared with VV-T7 (Fig. 7).
Low pH treatment of VV-PT7-luc virions bound to cells infected with
VV-T7ΔSPI-3ΔA56 gave greater luciferase expression than exposure to
pH 7 buffer (Fig. 7). Fig. 7 shows that luciferase expression resulting
from superinfection of cells infected with VV-T7ΔSPI-3ΔA56 was
higher than for VV-T7-infected cells, when cells treated at pH 7 are
compared, and when pH 5-treated cells are compared. Both SPI-3 and
A56 were detectable by immunoﬂuorescence at normal levels on the
surface of infected cells that had been treated at pH 5 (data not
shown), indicating that the proteins are still present following low pH
treatment. The fact that SPI-3/A56 in VV-T7 reduces luciferase
expression from superinfecting virus, even after low pH treatment
(Fig. 7), indicates that inhibition of virus fusion by SPI-3/A56 is not
abrogated by exposure to pH 5 buffer. The presence of SPI-3/A56 in the
membrane surrounding endocytosed virions in superinfected cells
would therefore be expected to slow the rate of virion entry into the
cytoplasm, even at the acidic conditions within endosomes.
Discussion
The construction of VV-PT7-luc with the luciferase reporter
coupled to the T7 promoter allowed us to follow virus entry at early
times following superinfection of VV-T7-infected cells. The strategy
was similar to previous studies where entry into uninfected cells was
followed by using luciferase as a sensitive reporter (Townsley et al.,
2006; Townsley and Moss, 2007), except that we used the T7
promoter rather than a strong early/late VV promoter to drive
luciferase expression. Under the conditions of our experiments,
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uninfected cells, by an extent that varied from approximately 30%
inhibition for CV-1 cells to 70% for HeLa monolayer cells (Fig. 1D and
data not shown). These data are consistent with the earlier
observation that the initial adsorption of the superinfecting virus
was decreased by up to 40% by prior infection of BSC-40 African green
monkey kidney cells (Christen et al., 1990). SPI-3 and A56 did not
contribute to this reduction by inhibiting binding of virus, but rather
appeared to reduce the rate of MV entry. The most likely mechanism
for this reduction is interaction of SPI-3/A56 with proteins in the
entry/fusion complex (Wagenaar and Moss, 2007), with resulting
inhibition of virus fusion and entry. The results with CPV-T7
derivatives indicated that CPV SPI-3/A56 are active in preventing
superinfection by the related orthopoxvirus VV. The entry complex
proteins A28, H2, L5, A16, A21, G3, G9, and J5 are between 97.3 and
99.2% conserved between CPV strain Brighton Red and VV strain WR.
In comparison the SPI-3 and A56 proteins of the two viruses are 94.9%
and 83.2% identical, respectively.
Our experiments do not address potential roles of SPI-3/A56 in the
outer envelope of EV. Theoretically, SPI-3/A56 in EV could negatively
regulate the activity of the entry/fusion complex until the outer
membrane has been removed by a non-fusogenic mechanism after
binding of EV to susceptible cells (Law et al., 2006). However, it is
difﬁcult to see how the presence of SPI-3/A56 on the outer surface of
the EV envelope would allow inhibition of the entry/fusion complex
on the surface of the MV, given that the two sets of proteins are
physically separated by an intervening membrane. SPI-3/A56 could
contribute to the stability of the EV envelope, so that fusogenic MV are
released more efﬁciently at neutral pH in the absence of SPI-3 or A56.
Alternatively A56 and/or SPI-3 could play an entirely different role, for
example in determining which cells EV binds to, i.e. tissue tropism.
Future experiments are aimed at assessing the biological conse-
quences of deletion of SPI-3 and A56 in appropriate animal models.
Materials and methods
Cells and antibodies
CV-1 African green monkey kidney cells (ATCC CCL-70) were
propagated in MEM with Earle's salts (Invitrogen) supplemented with
5% FBS, non-essential amino acids, penicillin/streptomycin, sodium
glutamate, and sodiumpyruvate (Cellgro). BSR-T7cells (namedBSR-T7/5
in Buchholz et al., 1999) were grown in DMEM with 8% FBS in the
presence of 10% CO2, and with G418 added at alternate passages.
SPI-3 mAb 4A11-4A3 has been described (Brum et al., 2003).
Plasmids and PCR constructs
The A56 gene of both CPV and VV was replaced with a gfp cassette
driven by the synthetic PE/L promoter (Chakrabarti et al., 1997). The
sequences ﬂanking the A56 gene were ampliﬁed by PCR and attached
to the PE/L-gfp cassette by ligation. The resulting A55R-gfp-A57R
product was obtained by PCR ampliﬁcation directly from the ligation
reaction.
The luciferase gene, originally from pGL3 (Promega), was inserted
into pTM1 (Moss et al., 1990) to create pTM1-luc, with luciferase
downstream from the T7 promoter and in between the left and right
ﬂanks of the TK gene. The wild-type A56 and SPI-3 genes and P1/P1′
and P5/P5′ site-directed SPI-3 mutants (Turner andMoyer, 1995) were
recloned into pSC65 (Chakrabarti et al., 1997) to allow expression from
the synthetic PE/L promoter following transfection.
Viruses
VV-T7 (vTF7-3, (Fuerst et al., 1986)) and VV-T7ΔSPI-3 with the SPI-
3 gene replaced by a gpt cassette conferring resistance to mycophe-nolic acid (Turner and Moyer, 1995) have been described previously.
VV-T7ΔSPI-3 ΔA56 was constructed by infecting cells with VV-
T7ΔSPI-3, transfecting with A55R-gfp-A57R DNA, and picking and
purifying plaques expressing gfp. Similarly VV-T7ΔA56 was derived
from VV-T7. The T7 RNA polymerase gene was inserted from the
plasmid pTF7-3 (Fuerst et al., 1986) into the TK gene of wtCPV to
construct CPV-T7. From CPV-T7, CPV-T7ΔSPI-3 was constructed by
insertion of a gpt cassette at the SPI-3 locus (Turner and Moyer, 1992),
and CPV-T7ΔA56 was isolated by replacing A56 with gfp. The double
mutant CPV-T7ΔSPI-3 ΔA56 was isolated by sequentially inactivating
the SPI-3 and A56 genes.
VV-PT7-luc with the luciferase gene under T7 control was isolated
following transfection of pTM1-luc DNA into cells infected with wt VV,
and selection for TK- recombinants by resistance to 5-bromo-2′-
deoxyuridine. Plaques containing the desired insertionwere identiﬁed
by expression of luciferase following infection of BSR-T7 cells.
Virus binding assay for VV A5-YFP
PuriﬁedMV of VV A5-YFP (Katsafanas andMoss, 2007) were bound
to CV-1 cells in 12-well plates for 1 h at room temperature atmoi=100.
After washing to remove unbound virions, PBS containing 0.05%
Saponin and 0.5 μg/ml DAPI was added to stain the nuclei. Cells with
bound virions were harvested by scraping, pelleted by centifrugation
for 3 min at 4000 g, and the pellets resuspended in 100 μl PBS before
transfer to a black 96-well plate. YFP was measured by excitation at
488 nmand emission at 530 nmwith a 515 nmcutoffﬁlter, andDAPI by
360 nm excitation and 464 nm emission (420 nm cutoff).
Luciferase assays following infection with VV-PT7-luc
CV-1 cells were grown to conﬂuence over 3 days in 96-well white,
clear-bottom plates, and either mock-infected or infected with a VV-
T7 or CPV-T7 derivative at a multiplicity of 5. At 16 h p.i.,
superinfecting VV-PT7-luc in 50 μl serum-free medium with 40 μg/
ml AraC was added per well at moi=100, and adsorbed for 1 h at room
temperature on a rocking platform. Following removal of the VV-PT7-
luc inoculum,100 μl medium containing 40 μg/ml AraC was added per
well, and the cells incubated at 37 °C. At intervals 100 μl BriteLite
luciferase reagent (PerkinElmer) was added per well, the well
contents mixed by pipetting, and luminescence measured in a
Molecular Devices SpectraMax M2 plate reader. For each time point
and virus, 4 replicate wells were used.
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